• CDELNs and Sertoli Cell Cycle Rescue in Testicular Injury

  2026-09-04

  This reference study identifies Cistanche deserticola exosome-like nanovesicles (CDELNs) as a plant-derived intervention for cyclophosphamide-induced testicular injury. Its mechanistic contribution is the linkage of Sertoli-cell uptake through heparan sulfate proteoglycans with delivery of miR159b-3p, suppression of P21, and recovery of CDK1-associated cell-cycle activity.

• Nadolol (SQ-11725) PK Workflow Guide

  2026-09-04

  Nadolol (SQ-11725) supports reproducible beta-adrenergic blockade studies while also enabling transporter-aware pharmacokinetic experiments. This guide connects cardiovascular assay design with disease-state PK insights, offering practical workflows for hypertension research, angina pectoris studies, and vascular headache research.

• Ivermectin Workflows for Parasitology Research

  2026-09-03

  Build more reliable ivermectin assays by combining solvent-aware formulation, dose-response design, motility and viability readouts, and host-cell selectivity controls. The workflow also explains how a pancreatic cancer study can sharpen assay logic without implying that ivermectin has been validated as a Gasdermin C therapy.

• RNA Pol II Inhibition Activates Apoptosis

  2026-09-03

  Harper et al. show that RNA Pol II inhibition kills cells through an active apoptotic program triggered by depletion of hypophosphorylated RNA Pol IIA, rather than through passive loss of transcription. The study defines the Pol II degradation-dependent apoptotic response, or PDAR, and provides a framework for interpreting the lethality of transcription-targeting drugs.

• RNA Pol II Loss and Transcription-Independent Cell Death

  2026-09-02

  Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic response triggered by loss of hypophosphorylated RNA Pol IIA, rather than simply through depletion of transcripts and proteins. The study defines the Pol II degradation-dependent apoptotic response (PDAR), providing a framework for interpreting transcription-targeting drugs and designing mechanistically resolved cell-death assays.

• AMD-070 Hydrochloride in CXCR4 Research

  2026-09-02

  Build reproducible migration, signaling, Waldenström macroglobulinemia, and anti-HIV research workflows around a soluble CXCR4 antagonist. AMD-070 hydrochloride supports reversible pathway inhibition, genotype-aware assay design, and controlled HIV entry inhibition experiments without committing to a single disease model.

• HyperTrap Heparin HP Column for Signaling Workflows

  2026-09-01

  The HyperTrap Heparin HP Column combines ready-to-use operation with high-resolution heparin affinity for fractionating growth factors, coagulation proteins, and nucleic acid-binding enzymes. This practical guide connects column-based enrichment to CCR7–Notch1 cancer-stemness research while emphasizing assay design, parameter control, and troubleshooting.

• N-MYC/eIF4G1 Survival Axis in inv(16) AML

  2026-09-01

  Peramangalam et al. identify a previously unrecognized MYCN enhancer and establish an N-MYC/eIF4G1 pathway that supports survival in inv(16) acute myeloid leukemia. The study connects disruption of CBFβ-SMMHC–RUNX1 signaling with downstream transcriptional and translational dependencies, providing a mechanistic framework for subtype-focused acute myeloid leukemia research.

• Merimepodib (VX-497) in Cell Assays

  2026-08-31

  Learn how Merimepodib (VX-497), SKU B1112, can support interpretable cell-proliferation, viability, and antiviral experiments through mechanism-led controls and practical handling. The article connects IMPDH inhibition with quantitative assay design, rescue experiments, formulation choices, and vendor evaluation.

• BHPF–GPER1 Signaling in Neuroblastoma Apoptosis

  2026-08-31

  The 2024 study identifies fluorene-9-bisphenol (BHPF) as a suspected GPER1 inhibitor that binds key receptor residues and disrupts agonist-evoked calcium signaling in human neuroblastoma cells. Its integrated use of molecular dynamics, receptor knockout, site-directed mutagenesis, and cellular assays provides a mechanistic framework for interpreting endocrine-disrupting effects beyond classical estrogen receptors.

• CCG-1423: A Practical RhoA Inhibitor Workflow

  2026-08-30

  CCG-1423 offers a pathway-focused way to investigate MRTF-A nuclear import, proliferation, invasion, and apoptosis without treating it as a direct ROCK1 kinase blocker. This workflow translates its mechanism into reproducible cancer research assays and carefully bounded exploratory studies of tight-junction or viral-entry biology.

• Nuclear cGAS Restricts L1 Retrotransposition

  2026-08-29

  The reference study identifies a nuclear genome-protection pathway in which CHK2-phosphorylated cGAS promotes TRIM41-dependent ubiquitination and degradation of L1 ORF2p. This mechanism connects DNA damage signaling with posttranslational suppression of retrotransposition and provides a framework for studying genome instability in aging and cancer.

• Batimastat (BB-94) for MMP Assay Design

  2026-08-28

  Batimastat (BB-94) provides broad, nanomolar MMP inhibition for connecting extracellular proteolysis with matrix remodeling, tumor invasion, and neuromuscular-junction development. This guide turns its biochemical profile into practical workflows, controls, troubleshooting steps, and a careful bridge from localized BDNF processing to cancer research.

• Merimepodib (VX-497) for IMPDH Assays

  2026-08-28

  Merimepodib (VX-497) provides a practical way to test how guanine-nucleotide supply controls lymphocyte proliferation, viral replication, and host-cell fitness. Its reversible, guanosine-sensitive activity makes it especially useful for separating IMPDH biology from nonspecific cytotoxicity in antiviral and immunology workflows.

• Everolimus (RAD001): Beyond Viability Endpoints

  2026-08-27

  Everolimus (RAD001) is an orally bioavailable mTOR pathway inhibitor whose apparent potency can reflect both growth arrest and cell death. This guide combines its FKBP12–mTOR mechanism with a more rigorous framework for cancer cell proliferation inhibition, apoptosis assays, and translational model selection.

8425 records 1/562 page Next 12345 下5页 Last page